Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Hematology and Blood Transfusion
Erschienen in:

22.10.2016 | Review Article

The Laboratory Diagnosis of the Antiphospholipid Syndrome

verfasst von: Jasmina Ahluwalia, Sreejesh Sreedharanunni

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

The Antiphospholipid Syndrome (APS) is classified based on the presence of both clinical and laboratory criteria. Both sets of criteria are subject to much review and intense research as it is becoming increasingly clear that no single test is specific for defining this autoimmune disorder. A number of leading international bodies have released guidelines in an attempt to improve the laboratory testing and reporting. The current review is an appraisal of some of the literature pertaining to the laboratory testing.
Literatur
1.
Khamashta M, Hughes GRV (1999) Hughes syndrome: a short history of the antiphospholipid syndrome. In: Schoenfeld Y (ed) The decade of autoimmunity. Elsevier Science BV
2.
Nayfe R, Uthman I, Aoun J, SaadAldin E, Merashli M, Khamashta MA (2013) Seronegative antiphospholipid syndrome. Rheumatology (Oxf Engl) 52:1358–1367CrossRef
3.
Meroni PL, Chighizola CB, Rovelli F, Gerosa M (2014) Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther 16:1–14CrossRef
4.
Forastiero R (2012) Bleeding in the antiphospholipid syndrome. Hematology (Amst Neth) 17(Suppl 1):153–155
5.
de Groot PG, Urbanus RT, Derksen RHWM (2012) Pathophysiology of thrombotic APS: Where do we stand? Lupus 21:704–707CrossRefPubMed
6.
Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368:1033–1044CrossRefPubMed
7.
de Groot PG, Meijers JCM (2011) β(2)–Glycoprotein I: evolution, structure and function. J Thromb Haemost JTH 9:1275–1284CrossRefPubMed
8.
Krilis SA, Giannakopoulos B (2014) Laboratory methods to detect antiphospholipid antibodies. Hematol Am Soc Hematol Educ Program 2014:321–328
9.
de Groot PG, Urbanus RT (2012) The significance of autoantibodies against β2-glycoprotein I. Blood 120:266–274CrossRefPubMed
10.
Lackner KJ, Müller-Calleja N (2016) Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma. J Thromb Haemost JTH 14:1117–1120CrossRefPubMed
11.
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311CrossRefPubMed
12.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost JTH 4:295–306CrossRefPubMed
13.
Cousins L, Pericleous C, Khamashta M, Bertolaccini ML, Ioannou Y, Giles I et al (2015) Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with “seronegative” antiphospholipid syndrome. Ann Rheum Dis 74:317–319CrossRefPubMed
14.
Pengo V, Testa S, Martinelli I, Ghirarduzzi A, Legnani C, Gresele P et al (2015) Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res 135:46–49CrossRefPubMed
15.
Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F et al (2011) Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118:4714–4718CrossRefPubMed
16.
Mustonen P, Lehtonen KV, Javela K, Puurunen M (2014) Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. Lupus 23:1468–1476CrossRefPubMed
17.
de Groot PG, Lutters B, Derksen RHWM, Lisman T, Meijers JCM, Rosendaal FR (2005) Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost JTH 3:1993–1997CrossRefPubMed
18.
de Laat B, Derksen RHWM, Urbanus RT, de Groot PG (2005) IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105:1540–1545CrossRefPubMed
19.
Banzato A, Pozzi N, Frasson R, De Filippis V, Ruffatti A, Bison E et al (2011) Antibodies to domain I of β(2)Glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res 128:583–586CrossRefPubMed
20.
Pengo V, Banzato A, Denas G, Jose SP, Bison E, Hoxha A et al (2013) Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 12:832–834CrossRefPubMed
21.
Forastiero R (2014) Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation. Lupus 23:1252–1254CrossRefPubMed
22.
Park SH, Jang S, Park C-J, Chi H-S (2016) Clinical application of revised laboratory classification criteria for antiphospholipid antibody syndrome: Is the follow-up interval of 12 weeks instead of 6 weeks significantly useful? BioMed Res Int 2016:2641526PubMedPubMedCentral
23.
Pengo V, Denas G, Padayattil SJ, Zoppellaro G, Bison E, Banzato A et al (2015) Diagnosis and therapy of antiphospholipid syndrome. Pol Arch Med Wewn 125:672–677PubMed
24.
Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M et al (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus anticoagulant/antiphospholipid antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost JTH 7:1737–1740CrossRefPubMed
25.
Rand JH, Wolgast LR (2012) Dos and don’ts in diagnosing antiphospholipid syndrome. Hematol Am Soc Hematol Educ Program 2012:455–459
26.
Devreese KMJ, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL et al (2014) Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 12:792–795CrossRefPubMed
27.
Keeling D, Mackie I, Moore GW, Greer IA, Greaves M (2012) British Committee for Standards in haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 157:47–58CrossRefPubMed
28.
Moore GW (2014) Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 40(2):163–171CrossRefPubMed
29.
De Craemer AS, Musial J, Devreese KM (2016) Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost 14(9):1779–1787. doi:10.​1111/​jth.​13389 CrossRefPubMed
30.
Simmons DP, Herskovits AZ, Battinelli EM, Schur PH, Lemire SJ, Dorfman DM (2016) Lupus anticoagulant testing using two parallel methods detects additional cases and predicts persistent positivity. Clin Chem Lab Med. doi:10.​1515/​cclm-2015-0790. pii: /j/cclm.ahead-of-print/cclm-2015-0790/cclm-2015-0790.xmlPubMed
31.
Ahluwalia J, Sreedharanunni S, Kumar N, Masih J, Bose SK, Varma N et al (2016) Thrombotic primary antiphospholipid syndrome: the profile of antibody positivity in patients from North India. Int J Rheum Dis 19(9):903–912CrossRefPubMed
32.
Meneghel L, Ruffatti A, Gavasso S, Tonello M, Mattia E, Spiezia L et al (2015) The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Clin Chem Lab Med 53:1083–1089CrossRefPubMed
33.
Oku K, Amengual O, Kato M, Bohgaki T, Horita T, Yasuda S et al (2016) Significance of fully automated tests for the diagnosis of antiphospholipid syndrome. Thromb Res 146:1–6CrossRefPubMed
34.
Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML (2015) The global anti-phospholipid syndrome score in primary APS. Rheumatology (Oxf Engl) 54:134–138CrossRef
35.
Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML (2013) GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxf Engl) 52:1397–1403CrossRef
36.
Sciascia S, Cuadrado MJ, Sanna G, Murru V, Roccatello D, Khamashta MA et al (2014) Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort. Arthritis Care Res 66:1915–1920CrossRef
Metadaten
Titel
The Laboratory Diagnosis of the Antiphospholipid Syndrome
verfasst von
Jasmina Ahluwalia
Sreejesh Sreedharanunni
Publikationsdatum
22.10.2016
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2017
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0739-y

Weitere Artikel der Ausgabe 1/2017

Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference

  • Review Article

Intriguing Morphology of IgG/Lambda Secreting Myeloma Cells

  • Images

NK/T Cell Lymphoma: A Tertiary Centre Experience

  • Original Article

Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype

  • Original Article

L-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients

  • Original Article

Retrospective Study of Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) as a First-Line Therapy for Advanced-Stage Extranodal NK/T Cell Lymphoma

  • Original Article

Neu im Fachgebiet Onkologie

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Knochenmarktransplantat als Chance für ältere AML-Patienten

Lange Zeit ist die Transplantation von hämatopoetischen Stammzellen nur bei jüngeren Patienten mit akuter myeloischer Leukämie praktiziert worden. Inzwischen profitieren auch Ältere davon. Ergebnisse einer Studie unterstützen dieses Vorgehen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise